Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
16/04/2024 13:12
April 16 (Reuters) - Eloxx Pharmaceuticals Inc
ELOX.PK :
* ELOXX PHARMACEUTICALS PROVIDES ELX-02 AND ZKN-013 PROGRAM
UPDATES
* ELOXX PHARMACEUTICALS INC: ELX-02 GRANTED ORPHAN DRUG
DESIGNATION (ODD) FROM U.S. FOOD AND DRUG ADMINISTRATION (FDA)
FOR TREATMENT OF ALPORT SYNDROME
* ELOXX PHARMACEUTICALS INC: SIGNED GLOBAL LICENSING
PARTNERSHIP
FOR ZKN-013 WITH ALMIRALL PHARMACEUTICALS WITH $3M UPFRONT AND
UP TO $470M IN MILESTONES
Source text for Eikon: ID:nGNX3cxvYh
Further company coverage: ELOX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome